Risk of <i>N</i>-Nitrosodimethylamine (NMDA) Formation With Ranitidine

Strauss, David G.; Florian, Jeffry; Keire, David A.

doi:10.1001/jama.2021.16261

Cited by 3 publications

(1 citation statement)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…40,41 Recently US Food and Drug Administration (FDA) reported that "acceptable" levels of Nnitrosodimethylamine (NDMA) were found in commercial ranitidine tablets, where the NDMA final quantity could vary due to the subsequent conditions of storage. 41,42 NDMA is a chemical shown to induce tumor formation in the gastrointestinal tract, liver, lungs, and kidneys in animals. 41 Taken together, nowadays H2-receptor antagonists can no longer be recommended to prevent NSAID gastropathy.…”

Section: Current Therapies Against Gastroenterophatymentioning

confidence: 99%

Gaseous mediators (H2S, NO and CO) a new approach in gastrointestinal protection

Pineda-Peña

Chávez-Piña²

2023

Mex J Med Res

View full text Add to dashboard Cite

Gastrointestinal damage is generated by a wide range of harmful agents, and is the result of the activation of inflammatory, oxidant and cytotoxic mechanisms, that together overwhelm the “mucosa defense” of the gastrointestinal (GI) tract. It is currently known that the mechanisms by which gastric damage is generated are slightly different from those that generate intestinal damage. The treatments available on the market such as citoprotectors, the use of selective Ciclooxigenase 2 (COX-2) inhibitors, the co-prescription of acid suppressive agents and the use of prostaglandin analogues are mainly focused on the mechanisms of gastric damage, and their use has begun to be limited due to its adverse effects at intestinal and cardiovascular level. Due to its multifactorial origin, the prevention and treatment of GI damage requires effective therapies that can protect both gastric and intestinal level modulating more than one mechanism. Recently, has been reported the contribution of gaseous mediators nitric oxide (NO), hydrogen sulfide (H2S) and carbon monoxide (CO) in many physiological processes in the gastrointestinal tract, including the maintenance of GI mucosal barrier integrity. Experimental evidence has shown promising results regarding the gastric safety of these gasotransmitters, especially those coupled to NSAIDs. This review will try to give a general overview of the mechanisms of gastric and intestinal damage, their main differences, the existing therapies for their treatment and the information available on gas transmitters with a brief description of roles of each of these gaseous molecules.

show abstract